Literature DB >> 10214563

Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile.

K Park1, D Verotta, S K Gupta, L B Sheiner.   

Abstract

A model for the pharmacodynamic effect of a drug (designated only X), and the use of the model to explore optimal input is described. The data analyzed here are from a crossover comparison study of the effect of 4 active treatments, yielding distinct concentration vs. time curves, plus placebo in 32 subjects. The model expresses total effect as the sum of placebo effect and (pure) drug effect. The latter allows for possible tolerance (found) and time effects (not found). Random effects allow interindividual differences to be expressed. Conditioning on the fitted model, a population optimal input profile is designed that obeys certain protocol constraints. The profile minimizes the expectation of a sum of squared differences between target effect and the resulting response over a given time interval. The target is a fixed constant, chosen to be either the individuals' maximum effect level in response to a baseline input regimen used in the study or the maximum effect level for the typical individual in the population in response to this regimen, as predicted from the model. The expectation is taken over the estimated nonparametric distribution of the 32 subjects' random effects. As one goal of early clinical studies of drugs may be to provide a basis for designing an optimal delivery profile (with respect to a specified loss function), we suggest this report as an example of a reasonable way to go about finding such a profile.

Mesh:

Substances:

Year:  1998        PMID: 10214563     DOI: 10.1023/a:1021068202606

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

1.  A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples.

Authors:  K E Fattinger; D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

2.  A nonparametric subject-specific population method for deconvolution: II. External validation.

Authors:  K E Fattinger; D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

3.  A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.

Authors:  J M Gries; I F Troconiz; D Verotta; M Jacobson; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1997-01       Impact factor: 6.875

4.  Pharmacodynamic model of tolerance: application to nicotine.

Authors:  H C Porchet; N L Benowitz; L B Sheiner
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

5.  Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics.

Authors:  D Katz; D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

6.  A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters.

Authors:  J Gaillot; J L Steimer; A J Mallet; J J Thebault; A Bieder
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

7.  Estimation and model selection in constrained deconvolution.

Authors:  D Verotta
Journal:  Ann Biomed Eng       Date:  1993 Nov-Dec       Impact factor: 3.934

Review 8.  An efficient control strategy for dosage regimens.

Authors:  C Hu; W S Lovejoy; S L Shafer
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

9.  Methods for evaluating optimal dosage regimens and their application to theophylline.

Authors:  O Richter; D Reinhardt
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-12

10.  Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective.

Authors:  D Z D'Argenio; J H Rodman
Journal:  J Pharmacokinet Biopharm       Date:  1993-04
  10 in total
  7 in total

Review 1.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 2.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

Review 4.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

5.  A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.

Authors:  Federico Galvanin; Carlo C Ballan; Massimiliano Barolo; Fabrizio Bezzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-04       Impact factor: 2.745

Review 6.  Psychopharmacology: concepts and opinions about the use of stimulant medications.

Authors:  James M Swanson; Nora D Volkow
Journal:  J Child Psychol Psychiatry       Date:  2009-01       Impact factor: 8.982

7.  Standard Error of Empirical Bayes Estimate in NONMEM® VI.

Authors:  Dongwoo Kang; Kyun-Seop Bae; Brett E Houk; Radojka M Savic; Mats O Karlsson
Journal:  Korean J Physiol Pharmacol       Date:  2012-04-24       Impact factor: 2.016

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.